Prosecution Insights
Last updated: October 04, 2026
Application No. 18/688,081

COMPOUNDS AND METHODS FOR MODULATING SPLICING

Final Rejection §DP
Filed
Feb 29, 2024
Priority
Aug 30, 2021 — provisional 63/238,430 +2 more
Examiner
SHIAO, REI TSANG
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Remix Therapeutics Inc.
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
46%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
1649 granted / 2066 resolved
+19.8% vs TC avg
Minimal -34% lift
Without
With
+-33.6%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 1m
Avg Prosecution
51 currently pending
Career history
2087
Total Applications
across all art units

Statute-Specific Performance

§101
1.9%
-38.1% vs TC avg
§103
29.3%
-10.7% vs TC avg
§102
8.8%
-31.2% vs TC avg
§112
29.7%
-10.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 2066 resolved cases

Office Action

§DP
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority and Status of Claims 1. This application is a 371 of PCT/US2022/075708 08/30/2022, which claims benefit of the provisional application: 63325171 03/30/2022, and 63238430 08/30/2021. 2. Amendment of claims 1,5, 77 and 87-88, cancelation of claims 7, 13, 20, 22, 28, 35, 43, 47, 49, 52, 57, 60, 64, 68-70, 75, 80, 82, and 94-95, and addition of claims 101-112 in the amendment filed on 7/28/2026 is acknowledged. Claims 1, 5, 71, 77, 87-88 and 101-112 are pending in the application. No new matter has been found. Since the newly added claims 101-112 are commensurate within the scope of invention, claims 1, 5, 71, 77, 87-88 and 101-112 are prosecuted in the case. Responses to Amendments/Arguments 3. The rejection of claims 87-88 under 35 U.S.C. 112 (a) has been overcome in the amendment filed on 7/28/2026. Since claims 94-95 have been canceled, therefore the rejection of claim 94-95 under 35 U.S.C. 112 (a) has been obviated herein. 4. Since claims 43, 70, 75, 77, 80, 82 and 94-95 have been canceled, therefore the rejection of claim 43, 70, 75, 77, 80, 82 and 94-95 under 35 U.S.C. 112 (b) has been obviated herein. 5. Since Kesicki et al. ‘730 does not disclose the instant compounds of formula (I), therefore it is distinct from the instant invention. The rejection of claim 1 under 35 U.S.C. 102 (a)(1) has been overcome in the amendment filed on 7/28/2026. 6. Since Kesicki et al. ‘730 does not disclose the instant compounds of formula (I), therefore it is distinct from the instant invention. The rejection of claim 1, 5, 71 and 87-88 under 35 U.S.C. 103 (a) has been overcome in the amendment filed on 7/28/2026. Since claims 7, 13, 20, 22, 28, 35, 43, 47, 49, 52, 57, 60, 64, 68-69, 71 and 95 have been canceled, therefore the rejection of claims 7, 13, 20, 22, 28, 35, 43, 47, 49, 52, 57, 60, 64, 68-69, 71 and 95 under 35 U.S.C. 103 (a) has been obviated herein. 7. Since a terminal disclaimer against Reynolds et al. ‘827 has not been filed to the Office, therefore the rejection of claim 1 under the obviousness-type double patenting over Reynolds et al. ‘827 is maintained. Applicant are requested to file a terminal disclaimer to overcome the rejection. 8. Claims 101-112 are neither anticipated nor rendered obvious over the record, and therefore are allowable. Claim Objections 9. Claim 5, 71, 77 and 87-88 are objected to as being dependent on rejected claim 1. 10. THIS ACTION IS MADE FINAL. Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for replying to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REI TSANG SHIAO whose telephone number is (571)272-0707. The examiner can normally be reached on 8:30 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REI TSANG SHIAO/ Rei-tsang Shiao, Ph.D.Primary Examiner, Art Unit 1691 September 21, 2026
Read full office action

Prosecution Timeline

Feb 29, 2024
Application Filed
Apr 28, 2026
Non-Final Rejection mailed — §DP
Jul 28, 2026
Response Filed
Sep 24, 2026
Final Rejection mailed — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747241
COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE
2y 11m to grant Granted Sep 29, 2026
Patent 12742193
Heterologous Carotenoid Production in Microorganisms
3y 9m to grant Granted Sep 22, 2026
Patent 12740958
COMPOSITIONS AND METHODS USING AT LEAST ONE GLYCINE OR DERIVATIVE THEREOF AND AT LEAST ONE LARGE NEUTRAL AMINO ACID AND/OR CATIONIC AMINO ACID OR PRECURSOR THEREOF
3y 3m to grant Granted Sep 22, 2026
Patent 12741975
FUSED POLYCYCLIC SUBSTITUTED 5-CARBOXYLIC ACID THIENOPYRIMIDINE DIONE COMPOUND AND USE THEREOF
3y 1m to grant Granted Sep 22, 2026
Patent 12735412
SMALL MOLECULE ANTAGONISTS FOR THE RELAXIN-3/RXFP3 SYSTEM
3y 0m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
46%
With Interview (-33.6%)
2y 1m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 2066 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month